Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rucaparib - Clovis Oncology

Drug Profile

Rucaparib - Clovis Oncology

Alternative Names: AG-014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib phosphate

Latest Information Update: 11 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research UK
  • Developer Bristol-Myers Squibb; Cancer Research UK; Clovis Oncology; Merck Sharp & Dohme; Roche; UNICANCER; University of California at San Francisco; University of Colorado at Denver; University of Oklahoma; University of Utah
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Prostate cancer
  • Phase II Breast cancer; Cervical cancer; Endometrial cancer; Pancreatic cancer; Urogenital cancer
  • Phase I/II Non-small cell lung cancer; Solid tumours
  • Phase I Gynaecological cancer
  • Suspended Malignant melanoma

Most Recent Events

  • 01 Nov 2019 Clovis Oncology withdraws a phase II trial of rucaparib in Cervical cancer (Late-stage disease, Adjuvant therapy) prior to enrolment due to lack of financial support (PO) (NCT03795272)
  • 11 Oct 2019 The National Institute for Health and Care Excellence (NICE) approves rucaparib for ovarian, fallopian tube or peritoneal cancer through the Cancer Drugs Fund
  • 30 Sep 2019 Efficacy data from a phase III ARIEL3 trial and pooled safety data from Study 10, ARIEL2 and ARIEL3 in Ovarian cancer released by Clovis Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top